» Articles » PMID: 37120291

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Overview
Journal Oncologist
Specialty Oncology
Date 2023 Apr 29
PMID 37120291
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Older patients with myelodysplastic syndromes (MDS), particularly those with no or one cytopenia and no transfusion dependence, typically have an indolent course. Approximately, half of these receive the recommended diagnostic evaluation (DE) for MDS. We explored factors determining DE in these patients and its impact on subsequent treatment and outcomes.

Patients And Methods: We used 2011-2014 Medicare data to identify patients ≥66 years of age diagnosed with MDS. We used Classification and Regression Tree (CART) analysis to identify combinations of factors associated with DE and its impact on subsequent treatment. Variables examined included demographics, comorbidities, nursing home status, and investigative procedures performed. We conducted a logistic regression analysis to identify correlates associated with receipt of DE and treatment.

Results: Of 16 851 patients with MDS, 51% underwent DE. patients with MDS with no cytopenia (n = 3908) had the lowest uptake of DE (34.7%). Compared to patients with no cytopenia, those with any cytopenia had nearly 3 times higher odds of receiving DE [adjusted odds ratio (AOR), 2.81: 95% CI, 2.60-3.04] and the odds were higher for men than for women [AOR, 1.39: 95%CI, 1.30-1.48] and for Non-Hispanic Whites [vs. everyone else (AOR, 1.17: 95% CI, 1.06-1.29)]. The CART showed DE as the principal discriminating node, followed by the presence of any cytopenia for receiving MDS treatment. The lowest percentage of treatment was observed in patients without DE, at 14.6%.

Conclusion: In this select older patients with MDS, we identified disparities in accurate diagnosis by demographic and clinical factors. Receipt of DE influenced subsequent treatment but not survival.

Citing Articles

Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes.

Adrianzen-Herrera D, Strumlowska A Curr Hematol Malig Rep. 2025; 20(1):6.

PMID: 39821758 DOI: 10.1007/s11899-025-00750-5.

References
1.
Watmough S, Flynn M . A review of pain management interventions in bone marrow biopsy. J Clin Nurs. 2011; 20(5-6):615-23. DOI: 10.1111/j.1365-2702.2010.03485.x. View

2.
Sharma R, Pannikottu J, Xu Y, Tung M, Nothelle S, Oakes A . Factors Influencing Overuse of Breast Cancer Screening: A Systematic Review. J Womens Health (Larchmt). 2018; 27(9):1142-1151. PMC: 6148722. DOI: 10.1089/jwh.2017.6689. View

3.
Neuner J, Nattinger A, Yen T, McGinley E, Nattinger M, Pezzin L . Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?. Breast Cancer Res Treat. 2019; 176(1):205-215. PMC: 6687306. DOI: 10.1007/s10549-019-05213-z. View

4.
Hicks L, Bering H, Carson K, Kleinerman J, Kukreti V, Ma A . The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Blood. 2013; 122(24):3879-83. DOI: 10.1182/blood-2013-07-518423. View

5.
Oster H, Crouch S, Smith A, Yu G, Shrkihe B, Baruch S . A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. Blood Adv. 2021; 5(16):3066-3075. PMC: 8405190. DOI: 10.1182/bloodadvances.2020004055. View